Gelteq Limited (NASDAQ:GELS) Sees Significant Decline in Short Interest

Gelteq Limited (NASDAQ:GELS) was the target of a large decrease in short interest in May. As of May 29th, there was short interest totaling 77,097 shares, a decrease of 36.3% from the May 14th total of 120,948 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 54,978 shares, the short-interest ratio is currently 1.4 days.

Institutional Investors Weigh In On Gelteq

A hedge fund recently bought a new stake in Gelteq stock. Susquehanna International Group LLP acquired a new position in shares of Gelteq Limited (NASDAQ:GELS) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 41,550 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned about 0.44% of Gelteq at the end of the most recent quarter.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Gelteq from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Gelteq Price Performance

NASDAQ GELS opened at $0.99 on Monday. Gelteq has a 52 week low of $0.39 and a 52 week high of $2.30. The stock has a fifty day moving average of $0.59 and a 200-day moving average of $0.78.

Key Headlines Impacting Gelteq

Here are the key news stories impacting Gelteq this week:

• Positive Sentiment: Gelteq said it successfully completed veterinary palatability trials with Kemin Industries, which supports the use of its proprietary gel-based delivery technology in animal-health applications and may help validate the platform for future partnerships and commercialization. Article Title
• Neutral Sentiment: GELS experienced multiple LULD-related trading halts on June 11, signaling extreme volatility and unusually high investor activity, but without any stated company-specific news in those halt notices.
• Negative Sentiment: The repeated pauses and heavy volume suggest the stock is being driven by speculation and volatility rather than fundamentals alone, which can pressure shares even when a positive operating update is released.

About Gelteq

Gelteq Inc is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc is based in NEW YORK.